King Faisal Specialist Hospital, Riyadh – United Arab Emirates
About Dr. Hazzaa Alzahrani
Dr. Hazzaa Alzahrani is the Director of the Adult Hematology and Stem Cell Transplant Division at a national tertiary cancer centre in Riyadh, Saudi Arabia, and one of the region's most senior adult hematologists. He is widely regarded as a leading adult hematology specialist Riyadh, Saudi Arabia with decades of experience in bone marrow failure, hemophilia, AML, and allogeneic transplantation.Director of Adult Hematology and Stem Cell Transplant Division at a major national referral centre.30+ years of experience in complex hematological and transplant care.Lead clinician for rare plasminogen deficiency and related rare-disease cases — successfully managed one of the world's first liver transplants for congenital plasminogen deficiency.Co-editor of multidisciplinary guidelines for the management of haematological malignancies.Active in the regional CAR T-cell therapy programme.Qualifications & Credentials
Medical Degrees
- MBBS
- Residency — Internal Medicine
Fellowships & Special Training
- Fellowship — Hematology
- Fellowship — Hematopoietic Stem Cell Transplantation
- Advanced Training — Hemostasis, Thrombosis & Bone Marrow Failure
Certifications & Accreditations
- Saudi Commission for Health Specialties (SCFHS) Registration
- Member — American Society of Hematology (ASH)
- Member — European Society for Blood and Marrow Transplantation (EBMT)
Areas of Expertise
Major Conditions Treated
- Acute Myeloid Leukemia (AML)
- Acute Lymphoblastic Leukemia (ALL)
- Chronic Myeloid Leukemia (CML)
- Multiple Myeloma
- Hodgkin & Non-Hodgkin Lymphoma
- Myelodysplastic Syndromes & Myeloproliferative Neoplasms
- Aplastic Anemia & Bone Marrow Failure Syndromes
- Hemophilia & Bleeding Disorders
- Sickle Cell Disease (Adult)
- Plasma Cell Leukemia & Rare Plasminogen Deficiency
Sub-specialties
- Adult Stem Cell Transplantation: Oversees matched-sibling, unrelated donor, and haploidentical HSCT as a core adult hematology specialist Riyadh, Saudi Arabia, with extensive experience in AML and high-risk hematologic malignancies.
- Hemostasis & Thrombosis: Diagnosis and long-term management of hemophilia A/B, von Willebrand disease, rare plasminogen deficiency, and complex coagulopathies, including novel extended half-life factor products.
- Bone Marrow Failure & Rare Syndromes: Expertise in acquired aplastic anemia, Fanconi anemia, ERCC6L2-associated BMF, and other inherited bone marrow failure syndromes.
Advanced Procedures & Treatments
- Induction & Consolidation Chemotherapy for Adult Leukemia
- Autologous Stem Cell Transplantation
- Allogeneic Stem Cell Transplantation (MUD & Haplo)
- Tyrosine Kinase Inhibitor Therapy for CML
- Blinatumomab & Inotuzumab for R/R B-ALL
- CAR T-cell Therapy (Kite / Commercial & Academic)
- Androgen & Immunosuppressive Therapy for Aplastic Anemia
- Recombinant & Extended Half-Life Factor Replacement for Hemophilia
Professional Experience
Current Affiliation
- King Faisal Specialist Hospital & Research Centre (KFSHRC), Riyadh, Saudi Arabia — Director, Adult Hematology & Stem Cell Transplant Division; Consultant, Department of Hematology, Stem Cell Transplantation and Cellular Therapy (Present)
Past Affiliations
- Information not publicly available.
Academic & Research Roles
- Editorial Board Member — Hematology/Oncology and Stem Cell Therapy journal
- Faculty — KFSHRC Hematology & HSCT Fellowship Programme
- Supervising Physician — Rare Haematology & Liver Transplant Multidisciplinary Programme
Key Achievements
- Director of one of the Middle East's largest adult HSCT programmes
- Supervised a world-first liver transplant for congenital plasminogen deficiency with 22-year follow-up care
- Co-author of KFSHRC Guidelines for the Management of Hematological Malignancies
- Co-author of hospital-based CAR T-cell manufacturing and Swift CAR-T platform publications
Awards & Recognitions
National & International Awards
- Information not publicly available.
Professional Memberships
- American Society of Hematology (ASH)
- European Society for Blood and Marrow Transplantation (EBMT)
- Eastern Mediterranean Blood and Marrow Transplantation Group (EMBMT)
- Saudi Society of Hematology
Research & Publications
Published Papers (Selected)
- Syed F, Warda W, Alqudairy H, …, Alfraih F, Alahmari A, Albabtain A, Hanbali A, Aljurf M, Alzahrani H, Saad A, Elfakih R. Disrupting the global CAR T paradigm from the Middle East: Ultra-fast Swift CAR T and scalable point-of-care manufacturing. Blood. 2025;146(Suppl 1):2406.
- Owaidah T, Bakr S, Al-Numair N, AbaAlkhail H, Alzahrani H, Saleh M, et al. Genotype Hemophilia Screening Program Identified 2 Novel Variants Including a Novel Variant Causing a Pathogenic Variant of the Factor 8 Gene. Clin Appl Thromb Hemost. 2023.
- Alasbali R, Alzahrani M, Alhayli S, Rasheed W, …, Saad A, Alzahrani HA, Almohareb F, Aljurf M, Kassim AA, Alahmari AD. Excellent Outcomes of HLA Matched Related Donor Transplant for Adults with Severe Sickle Cell Disease Using a Non-Myeloablative Conditioning. Blood. 2023;142(Suppl 1):1042.
Ongoing Research & Clinical Interests
- Long-term outcomes of allogeneic HSCT in AML and ALL
- Hemophilia genotype-phenotype correlation and extended half-life factor therapy
- CAR T-cell therapy and point-of-care cellular manufacturing
- Non-myeloablative HSCT for sickle cell disease in adults
Estimated Treatment Costs
| Procedure / Consultation | Estimated Cost (INR) | Estimated Cost (USD) |
|---|---|---|
| Hematology Consultation | ₹1,500 – ₹3,500 | $18 – $42 |
| Bone Marrow Biopsy & Aspiration | ₹15,000 – ₹35,000 | $180 – $420 |
| Autologous Stem Cell Transplant | ₹15,00,000 – ₹22,00,000 | $18,000 – $26,500 |
| Allogeneic Stem Cell Transplant (Matched) | ₹22,00,000 – ₹35,00,000 | $26,500 – $42,000 |
| CAR T-cell Therapy | ₹1,50,00,000 – ₹3,50,00,000 | $1,80,000 – $4,20,000 |
*Indicative estimates only. Actual costs subject to hospital pricing, case complexity, and insurance. Contact Cancer Rounds for a personalised quote.
Frequently Asked Questions
1. What advanced technologies does Dr. Hazzaa Alzahrani use in Adult Hematology & Stem Cell Transplantation treatment?
Dr. Hazzaa Alzahrani uses modern hematology tools including matched and haploidentical adult HSCT, commercial and academic CAR T-cell therapy, targeted therapy for CML (TKIs), extended half-life factor products for hemophilia, and molecular / MRD-based monitoring. Cancer Rounds can coordinate pre-travel virtual consultations for international patients.
2. What conditions does Dr. Hazzaa Alzahrani specialize in treating?
Dr. Hazzaa Alzahrani specialises in acute and chronic leukemias, multiple myeloma, lymphomas, aplastic anemia, bone marrow failure syndromes, hemophilia, rare bleeding disorders, and adult sickle cell disease — making him a trusted adult hematology specialist Riyadh, Saudi Arabia for best cancer treatment and second opinions.
3. How do I book an appointment with Dr. Hazzaa Alzahrani?
Appointments with Dr. Hazzaa Alzahrani can be booked directly through the Cancer Rounds website or by contacting their international patient department for priority scheduling.
4. Can international patients receive treatment from Dr. Hazzaa Alzahrani?
Yes. Cancer Rounds provides full assistance for international patients seeking treatment from Dr. Hazzaa Alzahrani, including medical visa invitation letters, airport transfers, and local accommodation coordination.
5. What support is available for international patients?
International patients benefit from a dedicated concierge service provided by Cancer Rounds, including language interpretation, financial counselling, and pre-travel virtual consultations to review medical records before arrival.
6. Does Dr. Hazzaa Alzahrani offer second opinions for Adult Hematology & Stem Cell Transplantation cases?
Yes. Second opinion consultations with Dr. Hazzaa Alzahrani can be arranged via Cancer Rounds for patients seeking an expert Adult Hematology and Stem Cell Transplant review of diagnosis, transplant eligibility, CAR-T candidacy, and long-term disease management in Riyadh, Saudi Arabia.
